232 related articles for article (PubMed ID: 9600216)
1. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas.
Tohma Y; Gratas C; Van Meir EG; Desbaillets I; Tenan M; Tachibana O; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Mar; 57(3):239-45. PubMed ID: 9600216
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.
Watanabe K; Tachibana O; Sata K; Yonekawa Y; Kleihues P; Ohgaki H
Brain Pathol; 1996 Jul; 6(3):217-23; discussion 23-4. PubMed ID: 8864278
[TBL] [Abstract][Full Text] [Related]
3. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme.
Kraus JA; Wenghoefer M; Glesmann N; Mohr S; Beck M; Schmidt MC; Schröder R; Berweiler U; Roggendorf W; Diete S; Dietzmann K; Heuser K; Müller B; Fimmers R; von Deimling A; Schlegel U
J Neurooncol; 2001 May; 52(3):263-72. PubMed ID: 11519857
[TBL] [Abstract][Full Text] [Related]
4. p53 mutations versus EGF receptor expression in giant cell glioblastomas.
Peraud A; Watanabe K; Plate KH; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1997 Nov; 56(11):1236-41. PubMed ID: 9370234
[TBL] [Abstract][Full Text] [Related]
5. Expression of vascular endothelial growth factor-b in human astrocytoma.
Gollmer JC; Ladoux A; Gioanni J; Paquis P; Dubreuil A; Chatel M; Frelin C
Neuro Oncol; 2000 Apr; 2(2):80-6. PubMed ID: 11303624
[TBL] [Abstract][Full Text] [Related]
6. Concurrent EGFR amplification and TP-53 mutation in glioblastomas.
Gil-Benso R; Lopez-Gines C; Benito R; López-Guerrero JA; Callaghan RC; Pellín A; Roldán P; Cerdá-Nicolas M
Clin Neuropathol; 2007; 26(5):224-31. PubMed ID: 17907599
[TBL] [Abstract][Full Text] [Related]
7. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
[TBL] [Abstract][Full Text] [Related]
8. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.
Biernat W; Kleihues P; Yonekawa Y; Ohgaki H
J Neuropathol Exp Neurol; 1997 Feb; 56(2):180-5. PubMed ID: 9034372
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of p53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis.
Khalid MH; Yagi N; Hiura T; Shibata S
Brain Tumor Pathol; 1998; 15(2):89-94. PubMed ID: 10328545
[TBL] [Abstract][Full Text] [Related]
10. Primary and secondary glioblastomas: from concept to clinical diagnosis.
Kleihues P; Ohgaki H
Neuro Oncol; 1999 Jan; 1(1):44-51. PubMed ID: 11550301
[TBL] [Abstract][Full Text] [Related]
11. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma.
Yoon KS; Lee MC; Kang SS; Kim JH; Jung S; Kim YJ; Lee JH; Ahn KY; Lee JS; Cheon JY
J Korean Med Sci; 2001 Aug; 16(4):481-8. PubMed ID: 11511795
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.
Maity A; Pore N; Lee J; Solomon D; O'Rourke DM
Cancer Res; 2000 Oct; 60(20):5879-86. PubMed ID: 11059786
[TBL] [Abstract][Full Text] [Related]
13. The definition of primary and secondary glioblastoma.
Ohgaki H; Kleihues P
Clin Cancer Res; 2013 Feb; 19(4):764-72. PubMed ID: 23209033
[TBL] [Abstract][Full Text] [Related]
14. Genetic pathways to primary and secondary glioblastoma.
Ohgaki H; Kleihues P
Am J Pathol; 2007 May; 170(5):1445-53. PubMed ID: 17456751
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia and VEGF mRNA expression in human tumors.
Ziemer LS; Koch CJ; Maity A; Magarelli DP; Horan AM; Evans SM
Neoplasia; 2001; 3(6):500-8. PubMed ID: 11774032
[TBL] [Abstract][Full Text] [Related]
16. [Study on the expression of epidermal growth factor receptor and p53 in astrocytic gliomas: evidence for a distinct genetic pathway].
Dong L; Pu PY; Wang H; Wang GX; Kang CS; Jiao DR
Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):232-6. PubMed ID: 16776982
[TBL] [Abstract][Full Text] [Related]
17. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis.
Valter MM; Hügel A; Huang HJ; Cavenee WK; Wiestler OD; Pietsch T; Wernert N
Cancer Res; 1999 Nov; 59(21):5608-14. PubMed ID: 10554042
[TBL] [Abstract][Full Text] [Related]
18. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas.
Sure U; Rüedi D; Tachibana O; Yonekawa Y; Ohgaki H; Kleihues P; Hegi ME
J Neuropathol Exp Neurol; 1997 Jul; 56(7):782-9. PubMed ID: 9210874
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis.
Sonoda Y; Kanamori M; Deen DF; Cheng SY; Berger MS; Pieper RO
Cancer Res; 2003 Apr; 63(8):1962-8. PubMed ID: 12702589
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors.
Cheng Y; Ng HK; Ding M; Zhang SF; Pang JC; Lo KW
J Neuropathol Exp Neurol; 1999 Feb; 58(2):120-8. PubMed ID: 10029095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
